osis and Blood Transfusion Center, Taranto, Italy;4Thrombosis and Blood Transfusion, “Di Venere” Hospital, Bari, Italy; Thrombosis Center, Department of Clinical Pathology, Altamura,Italy; 6Thrombosis and Blood Transfusion Center, Molfetta, Italy;Department of Hematology, CCR4 Antagonist supplier Acquaviva delle Fonti, Italy; 8Hemostasisand Thrombosis Center, Nocera Inferiore-Pagani-Scafati, Italy;Department of Internal Medicine, Gallipoli, Italy; 10Hemostasis Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, A. Division of Interdisciplinary Medicine, University of Bari, Bari,and Blood Transfusion Center, “San Paolo” Hospital, Bari, Italy;Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy;Italy Background: Oral anticoagulant therapy has been historically managed in Italy in individuals with atrial fibrillation (AF) by a network of Anticoagulation Centers (ACs). Individuals taking direct oral anticoagulants (DOACs) no longer needed periodical blood withdrawal for the modification on the drug dosage and for that reason their follow-up might be much less strict than ahead of. From 2018 onwards, 19 ACs of southern Italy have been applying a clinical model, named EGINA (Excellence model for the Integrated Management of New Anticoagulants), designed to improve the management of such individuals. Aims: To evaluate the incidence of ischemic and hemorrhagic events in sufferers taking DOACs, followed as outlined by the EGINA model. Methods: This multi-center study included patients with AF who began a DOAC from Jan 2018 to Feb 2020. Data had been collected retrospectively by 9 ACs of southern Italy. The observational period lasted a maximum of 12 months in the date of initiation of therapy with a DOAC. Diagnosis of major and minor bleeding was created in accordance with the International Society on Thrombosis and Haemostasis (ISTH). Final results: All round 395 individuals with AF has been assessed. Imply age was 75.76 years (SD = 9.48, ranging from 31 to 100 years old) and 170 individuals had been female (43 ). On average, at baseline assessment CHA2DS2-VASc score was 3.49 (SD = 1.3) and HAS-BLED 1.79 (SD = 0.95). The 33.two of sufferers have been na e for anticoagulation. Apixaban was essentially the most prescribed DOACs (35.4 ), followed by edoxaban (32.4 ), rivaroxaban (17.0 ) and dabigatran (15.2 ). DoseABSTRACT789 of|Aims: Examine the price of Stroke/SE (Ischemic, Hemorrhagic, Other) and Key Bleeding (ICH, GI, other internet site) events and linked healthcare fees amongst NVAF patients prescribed oral anticoagulants (OACs). Strategies: Elderly sufferers having a NVAF diagnosis and OAC prescription (received January 1, 2013 – December 31, 2017) were identified inside the fee-for-service Medicare claims database. Patients were followed from OAC initiation to discontinuation, switch, disenrollment, death, or study finish. Stroke/SE and MB associated hospitalizations and connected IL-6 Inhibitor Compound expenses had been identified applying ICD-9 and ten principal diagFIGURE 1 Trough and peak degree of dabigatran in patient who received 110mg compared with 150mg of dabigatran as outlined by creatinine clearance nosis codes. Benefits: 738,283 patients with NVAF have been included (apixaban: 34.0 , dabigatran: 5.six , rivaroxaban: 26.7 , warfarin: 33.6 ). Individuals typical age was 78 years with mean CHA 2DS2-VASc score of 4.5 and HAS-BLED score of three.four. Mean follow-up time was 300.5 days. three.7 of patients had a MB (GI: 1.9 , ICH: 0.6 , Other: 1.5 ). Among sufferers with MB, MB-related average total medical charges were 19,505 as well as the PPPM price amongst all individuals was 171. GI bleed had the low